TIVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tivic Health Systems Inc (TIVC) is not a strong buy for a beginner investor with a long-term strategy at this time. While there are potential positive catalysts related to government collaboration and FDA designations, the company's financial performance is weak, with no revenue growth and significant losses. Additionally, technical indicators and trading trends do not suggest a strong entry point, and there are no proprietary trading signals to support a buy decision. Holding off on this stock for now is advisable.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is in the neutral zone, and moving averages are converging, showing no clear trend. The stock is trading near its resistance levels (R1: 1.097, R2: 1.163), which may limit further upside in the short term.
The company is presenting its Entolimod™ TLR5 agonist at the U.S. Department of Defense's Tech Watch program, indicating potential government collaboration. The technology has Fast Track and Orphan Drug designations from the FDA, and it is being positioned as a key component in national defense stockpiles.
The company's financials show no revenue growth, significant losses, and declining EPS. There are no significant hedge fund or insider trading trends to suggest confidence in the stock.
In Q4 2025, Tivic Health reported no revenue growth, a net income loss of -$3,027,000 (up 104.94% YoY), and a significant drop in EPS to -1.65 (-48.44% YoY). Gross margin remains at 0.
No analyst rating or price target changes are available for this stock.
